Tuesday, September 11, 2012

EISAI PARTNERS WITH THE SABIN VACCINE INSTITUTE IN AN EFFORT TO DEVELOP VACCINES FOR NEGLECTED TROPICAL DISEASES

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, “Eisai”) announced today that it has
entered into a partnership agreement to supply the Sabin Vaccine Institute (Headquarters: Washington
D.C., President: Dr. Peter Hotez, “Sabin”) with E6020, an in-house developed adjuvant that enhances the
immune effects of vaccines, as well as all relevant information pertaining to the compound free of charge,
to support the development of vaccines for two neglected tropical diseases (NTDs)-Chagas disease and
leishmaniasis. E6020 stimulates the body’s immune system via TLR4 (Toll-like receptor 4), a receptor that
plays a key role in the body’s innate immune system., and is expected to be used in a broad range of
antigen vaccines to enhance vaccine efficacy.
Sabin is a non-profit organization dedicated to conducting research into therapeutic vaccines and NTDs.
The institute works with governments, leading public and private organizations, and academic institutions
on the research and development of innovative vaccines for vaccine preventable and NTDs, while at the
same time advocating increased access to medical treatments.
Chagas disease and leishmaniasis are classified as diseases requiring innovative and intensified disease
management (IDM) given their difficultly to diagnose and treat compared to other NTDs. This partnership
is a new Product Development Partnership which integrates Sabin’s strengths in the research and
development of vaccines for NTDs and Eisai’s compound and knowledge as a research and
development-based pharmaceutical company, and which will seek to develop vaccines for these diseases
as early and efficiently as possible.
Eisai is a signatory to the London Declaration, a coordinated effort to eliminate 10 NTDs by 2020 through
the largest global public-private partnership to date. As part of its commitment under the Declaration, Eisai
has entered into this partnership with Sabin, and has also agreed to produce at its Vizag Plant in India 2.2
billion tablets of DEC (diethylcarbamazine), a lymphatic filariasis medicine currently in short supply globally,
and supply it to the World Health Organization (WHO) free of charge from 2013.
As it expands its business in both emerging and developing nations in this era of great globalization, Eisai
considers its contributions to the economic development and expansion of the middle-income class
through the enhancement of health and welfare in these countries as a form of long-term investment for
future growth. Going forward, Eisai is committed to taking proactive steps to address issues related to
access to medicines, including NTDs, as it seeks to make further contributions to increase the benefits
provided to patients and their families worldwide.

Source - Eisai